Daraxonrasib earns breakthrough designation for pancreatic cancer
The FDA has granted breakthrough therapy designation to daraxonrasib for metastatic pancreatic cancer with KRAS G12 mutations.
rarecancernews.comI can’t reliably pull the very latest updates right now because my web-access tools are unavailable for this turn. But I can share several recent, sourced items about daraxonrasib (RMC-6236) and its KRAS / pan-RAS target that should help you orient to the current news cycle:
What daraxonrasib targets (protein target)
- Daraxonrasib is described as a RAS(ON) inhibitor that targets active, GTP-bound RAS signaling, with emphasis on KRAS-driven cancers (including multiple KRAS mutation variants).
Recent news highlights (time-stamped)
- 2026-05-10: A report highlights daraxonrasib’s developing profile in metastatic pancreatic cancer, framing it as a new targeted approach against KRAS-driven disease.
- 2026-05-07: Social/press commentary discusses reported Phase 3 outcomes for daraxonrasib in previously treated metastatic pancreatic cancer (e.g., median overall survival comparisons vs chemotherapy).
- 2026-05-05: A EurekAlert release reports initial anti-tumor activity for daraxonrasib in RAS-mutant pancreatic cancer, attributed to Phase 1/2 results from MD Anderson researchers.
- 2026-04-19: Coverage focuses on daraxonrasib and its implications for pancreatic cancer patients.
Peer-reviewed/biological (mechanism) update
- 2025-08-07 (PLOS ONE): A study reports daraxonrasib (pan-RAS inhibitor, RMC-6236) effects in osteosarcoma, with findings tied to KRAS mutant cell responses and downstream signaling changes (e.g., pathways linked to AKT/ETS1 and metastasis-associated factors).
If you tell me what you mean by “latest” (e.g., “past 7 days” vs “past month”) and whether you want clinical-trial news only or also lab/mechanism papers, I can narrow this to a tighter, up-to-date roundup once access to live sources is working again.
Sources:[1][4][7][10]